Loading...
Loading...
OKYO| Name | Value |
|---|---|
| Revenues | 0.0 |
| Cost of Revenue | 3,370.0 |
| Gross Profit | -3,370.0 |
| Operating Expense | 3,642.0 |
| Operating I/L | -7,014.0 |
| Other Income/Expense | -1,052.0 |
| Interest Income | 0.0 |
| Pretax | -8,068.0 |
| Income Tax Expense | 60.4 |
| Net Income/Loss | -8,008.0 |
OKYO Pharma Limited is a preclinical biopharmaceutical company based in the United Kingdom. The company specializes in developing therapeutics for inflammatory eye diseases and ocular pain. Its lead product, OK-101, is designed for the treatment of dry eye disease, while OK-201 is a preclinical candidate for neuropathic ocular pain. OKYO Pharma Limited generates revenue through the development and potential commercialization of these innovative therapeutics, aiming to address unmet medical needs in the ophthalmology market.
